TERF2IP and central nervous system cancer: miR-1246, enriched in sEVs derived from hypoxic glioma cells, targets the telomeric repeat-binding factor 2-interacting protein 1 (TERF2IP), which subsequently downregulates the NFκB pathway and activates the STAT3 pathway, leading to M2 macrophage polarization [66].